Search results
Results from the WOW.Com Content Network
Craig M. Crews (born June 1, 1964) is an American scientist at Yale University known for his contributions to chemical biology.He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that "hijack" cellular processes by inducing the interaction of two proteins inside a living cell. [1]
This concept underlaid the launch of numerous biotechnology companies including Arvinas, C4 Therapeutics, and Kymera. The Deshaies group also identified small molecules that inhibit targeting of substrates to the proteasome [24] and removal of ubiquitin chains from substrates by Rpn11. [25]
Some of the key B7-H3 inhibitors in the pipeline include Ifinatamab deruxtecan (I-DXd), Vobramitamab duocarmazine, Enoblituzumab, GSK5764227/HS-20093, and others.
DelveInsight’s 'Prostate Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline prostate cancer in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.
New York, USA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight. The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver.
Arkin was a founding scientist at Sunesis Pharmaceuticals, [4] where she helped discover and develop the anti-inflammatory drug lifitigrast (developed by SARcode/Shire), and anti-cancer experimental therapeutic vosaroxin (Sunesis).
The R&D pipeline involves various phases that can broadly be grouped in 4 stages: discovery, pre-clinical, clinical trials and marketing (or post-approval). Pharmaceutical companies usually have a number of compounds in their pipelines at any given time. The drug pipeline is an important indicator of the value and future prospects of a company ...
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma, Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical ...